Carcinoma que surge das células epiteliais glandulares do rim
Introdução
O que você precisa saber de cara
O carcinoma de células renais é um tipo de câncer que se desenvolve nas células epiteliais dos rins, afetando principalmente pessoas adultas. Além do tumor renal, o quadro pode vir acompanhado de pressão alta, palpitações, fraqueza nos músculos, suor excessivo e alterações hormonais ou na visão. Diversas alterações genéticas podem estar associadas à doença, como alterações nos genes VHL, FLCN e TERT. No Brasil, o tratamento pelo SUS é conduzido conforme a autonomia de cada serviço de saúde credenciado, seguindo as diretrizes diagnósticas estabelecidas.
Carcinoma que surge das células epiteliais glandulares do rim
Tem tratamento?
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 24 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 49 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
30 genes identificados com associação a esta condição. Padrão de herança: Not applicable.
Curadoria gene-doença
fontes oficiaisIntellectual developmental disorder, autosomal dominant 56
A form of intellectual disability, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period.
Hepatic adenomas familial
Rare benign liver tumors of presumable epithelial origin that develop in an otherwise normal liver. Hepatic adenomas may be single or multiple. They consist of sheets of well-differentiated hepatocytes that contain fat and glycogen and can produce bile. Bile ducts or portal areas are absent. Kupffer cells, if present, are reduced in number and are non-functional. Conditions associated with adenomas are insulin-dependent diabetes mellitus and glycogen storage diseases (types 1 and 3).
Renal cell carcinoma
Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into clear cell renal carcinoma (non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Clear cell renal cell carcinoma is the most common subtype.
Colorectal cancer
A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.
Pheochromocytoma
A catecholamine-producing tumor of chromaffin tissue of the adrenal medulla or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of epinephrine and norepinephrine, is hypertension, which may be persistent or intermittent.
Aniridia 2
A form of aniridia, a congenital, bilateral, panocular disorder characterized by complete absence of the iris or extreme iris hypoplasia. Aniridia is not just an isolated defect in iris development but it is associated with macular and optic nerve hypoplasia, cataract, corneal changes, nystagmus. Visual acuity is generally low but is unrelated to the degree of iris hypoplasia. Glaucoma is a secondary problem causing additional visual loss over time.
Carney complex 1
CNC is a multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac and other myxomas, endocrine tumors, and psammomatous melanotic schwannomas.
Birt-Hogg-Dube syndrome 1
A form of Birt-Hogg-Dube syndrome, a rare genodermatosis usually manifesting in adulthood and characterized by multiple fibrofolliculomas, trichodiscomas, and acrochordons. Patients with this syndrome have an increased susceptibility to develop renal cell carcinoma, lung cysts, and spontaneous pneumothorax. Inheritance is autosomal dominant.
Renal cell carcinoma
Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into clear cell renal carcinoma (non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Clear cell renal cell carcinoma is the most common subtype.
Waardenburg syndrome 2A
WS2 is a genetically heterogeneous, autosomal dominant disorder characterized by sensorineural deafness, pigmentary disturbances, and absence of dystopia canthorum. The frequency of deafness is higher in WS2 than in WS1.
Renal cysts and diabetes syndrome
An autosomal dominant disorder comprising non-diabetic renal disease resulting from abnormal renal development, and diabetes, which in some cases occurs earlier than age 25 years and is thus consistent with a diagnosis of maturity-onset diabetes of the young (MODY5). The renal disease is highly variable and includes renal cysts, glomerular tufts, aberrant nephrogenesis, primitive tubules, irregular collecting systems, oligomeganephronia, enlarged renal pelves, abnormal calyces, small kidney, single kidney, horseshoe kidney, and hyperuricemic nephropathy. Affected individuals may also have abnormalities of the genital tract.
Aniridia 1
A congenital, bilateral, panocular disorder characterized by complete absence of the iris or extreme iris hypoplasia. Aniridia is not just an isolated defect in iris development but it is associated with macular and optic nerve hypoplasia, cataract, corneal changes, nystagmus. Visual acuity is generally low but is unrelated to the degree of iris hypoplasia. Glaucoma is a secondary problem causing additional visual loss over time.
Aniridia 3
A form of aniridia, a congenital, bilateral, panocular disorder characterized by complete absence of the iris or extreme iris hypoplasia. Aniridia is not just an isolated defect in iris development but it is associated with macular and optic nerve hypoplasia, cataract, corneal changes, nystagmus. Visual acuity is generally low but is unrelated to the degree of iris hypoplasia. Glaucoma is a secondary problem causing additional visual loss over time.
Renal cell carcinoma
Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into clear cell renal carcinoma (non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Clear cell renal cell carcinoma is the most common subtype.
Intellectual developmental disorder, X-linked, syndromic, with pigmentary mosaicism and coarse facies
A disorder characterized by severe developmental delay with impaired intellectual development and poor speech, coarse facial dysmorphisms, and Blaschkoid pigmentary mosaicism. Additional clinical features may include epilepsy, orthopedic abnormalities, hypotonia, and growth abnormalities. The disorder affects both males and females.
Pheochromocytoma
A catecholamine-producing tumor of chromaffin tissue of the adrenal medulla or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of epinephrine and norepinephrine, is hypertension, which may be persistent or intermittent.
Medicamentos aprovados (FDA)
3 medicamentos encontrados nos registros da FDA americana.
Variantes genéticas (ClinVar)
1.376 variantes patogênicas registradas no ClinVar.
Classificação de variantes (ClinVar)
Distribuição de 32.171 variantes classificadas pelo ClinVar.
Vias biológicas (Reactome)
165 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Carcinoma de células renais
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
Com ensaio aberto em 40 países. O ponto verde marca onde há vaga agora.
🟢 Recrutando agora
100 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
Publicações mais relevantes
Mostrando amostra de 200 publicações de um total de 29.695
ODF3B Promotes the Progression of Clear Cell Renal Cell Carcinoma via the JAK/STAT Signaling Pathway.
BACKGROUND Clear cell renal cell carcinoma (ccRCC) is the most common renal malignancy, often associated with poor prognosis due to metastasis and treatment resistance. The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is a major oncogenic driver in ccRCC, but its upstream regulators remain unclear. Outer dense fiber of sperm tails 3B (ODF3B), initially identified in sperm flagella, shows aberrant expression in a subset of human malignancies, and emerging transcriptomic data suggest notable dysregulation of ODF3B in ccRCC, although its functional role in this tumor type remains unknown. MATERIAL AND METHODS ODF3B expression was analyzed using data from The Cancer Genome Atlas (TCGA) and validated in ccRCC cell lines. Prognostic significance was evaluated through clinicopathological and survival analyses. Functional assays, including Cell Counting Kit 8, colony formation, wound healing, Transwell assay, and flow cytometry, were performed after ODF3B knockdown in 786-O and OSRC-2 cells. Pathway enrichment analyses and Western blotting were used to explore mechanisms, and rescue experiments were conducted with the STAT3 agonist Colivelin TFA. RESULTS ODF3B was markedly upregulated in ccRCC tissues and cells, with high expression correlating with advanced stage, metastasis, and poor survival. ODF3B silencing suppressed proliferation, migration, and invasion while enhancing apoptosis, accompanied by reduced BCL2 and increased cleaved caspase-3. Bioinformatics revealed strong enrichment of JAK/STAT signaling in tumors with high expression of ODF3B. Mechanistically, ODF3B knockdown decreased phosphorylation of JAK1/2/3 and STAT3, whereas STAT3 activation rescued proliferative and anti-apoptotic effects. CONCLUSIONS ODF3B acts as a novel oncogenic driver in ccRCC by activating JAK/STAT signaling. Its overexpression predicts aggressive features and poor prognosis, highlighting ODF3B as a potential therapeutic target.
MAGI3 deficiency unleashes β-catenin conformational change to drive metastatic progression and mTOR inhibitor resistance in ccRCC.
Metastatic clear cell renal cell carcinoma (ccRCC) remains lethal due to therapy resistance, and while dysregulated Wnt/β-catenin signaling drives progression, its post-translational regulation is poorly understood. Through multi-omics analysis of TCGA/GEO datasets, we identified MAGI3 as a key metastasis suppressor in ccRCC. Functional validation revealed that MAGI3 loss enhances invasion, migration and metastatic potential in vitro and in vivo. Mechanistically, MAGI3 binds β-catenin's C-terminus via PDZ domains, disrupting intramolecular N-terminus-ARM domain interactions to expose phosphorylation sites, thereby enabling GSK-3β-mediated β-catenin phosphorylation and ubiquitin-dependent degradation. Critically, low MAGI3 hyperactivates β-catenin and drives mTOR inhibitor resistance. Combining Everolimus with the Wnt inhibitor XAV-939 slashed viability and invasion in resistant cells. Clinically, patients whose tumors exhibited high MAGI3 and low β-catenin expression demonstrated significantly improved response to Everolimus therapy. In conclusion, MAGI3 is a critical gatekeeper of β-catenin destruction in ccRCC. Its loss defines a metastatic, therapy-resistant subtype targetable by dual mTOR/Wnt blockade. Therefore, MAGI3 expression may stratify patients for personalized therapy.
DR5/WDR12 balances p65 stability promoting sunitinib resistance in renal cell carcinoma.
Although the use of tyrosine kinase inhibitors (TKIs), such as sunitinib, has led to impressive advancements in the treatment of clear cell renal cell carcinoma (ccRCC), primary or acquired resistance to sunitinib remains elusive. Here, we report that death receptor 5 (DR5) is upregulated in ccRCC tissues and sunitinib-resistant cells, and is associated with poor outcomes and sunitinib resistance. Gain- and loss-of-function experiments revealed that DR5 promotes sunitinib resistance both in vitro and in vivo. Mechanistically, DR5 enhances the activation of NF-κB signalling by reducing the ubiquitin-mediated proteasomal degradation of p65 via competitive binding to the CUL4B-DDB1 E3 ligase complex linker protein WDR12, leading to the transcriptional upregulation of DR5 and BCL2. The positive feedback loop between DR5 and p65 contributes to the upregulation of BCL2 expression, which in turn modulates sunitinib resistance in ccRCC. Notably, targeting the DR5/NF-κB/BCL2 axis sensitizes ccRCC cells to sunitinib both in vitro and in vivo. Clinically, ccRCC patients with high DR5 expression show decreased responsiveness to TKI-based therapy. Collectively, these results highlight the importance of the positive feedback loop involving the DR5/NF-κB axis in sunitinib resistance and provide an effective therapeutic strategy for overcoming resistance.
TRIM21-Mediated ubiquitination of FBL suppresses PI3K/AKT signaling and tumor progression in clear cell renal cell carcinoma.
Clear cell renal cell carcinoma (ccRCC) frequently exhibits transcriptional reprogramming driven by oncogenic C-Myc. Fibrillarin (FBL), a nucleolar C-Myc target, is markedly upregulated in ccRCC, correlating with poor prognosis and essential for tumor cell survival. Integrated single-cell RNA sequencing, bulk transcriptomics, and proteomics were used to identify FBL as a key target. Functional assays, immunoprecipitation-mass spectrometry, and molecular docking were performed to investigate FBL's oncogenic mechanisms and interaction with TRIM21. FBL promotes ccRCC cell proliferation, migration, and tumor growth via PI3K/AKT pathway activation. TRIM21 was identified as a novel FBL-binding E3 ubiquitin ligase that catalyzes K48-linked polyubiquitination of FBL at lysine 292, accelerating its proteasomal degradation. TRIM21 overexpression reduces FBL levels, inhibits PI3K/AKT signaling, and reverses FBL-induced oncogenic phenotypes. TRIM21 is downregulated in ccRCC tissues and associated with unfavorable prognosis. The TRIM21-FBL axis regulates ccRCC progression by modulating PI3K/AKT signaling, providing mechanistic insight and potential therapeutic targets for ribosome biogenesis and oncogenic signaling.
ZBED6-IGF2-PIK3C3 autophagy axis drives ccRCC progression: A multi-omics integration study.
Autophagy supports clear cell renal cell carcinoma (ccRCC) progression, yet its upstream regulatory mechanisms remain to be fully defined. Integrating bulk, single-cell, and spatial transcriptomics, we identify a regulatory axis wherein the transcription factor ZBED6 activates the expression of the autophagy-initiating kinase PIK3C3 via the repression of IGF2, thereby driving pro-tumorigenic autophagy. Spatial analysis confirms the co-localization of ZBED6 and PIK3C3 in tumor tissues. Using genes associated with this axis, we develop a six-gene prognostic signature that stratifies patients with distinct survival outcomes and differential responses to immunotherapy and targeted therapy. Functional assays show that ZBED6 promotes ccRCC cell proliferation, migration, and invasion. This work elucidates a pathway governing autophagy in ccRCC and provides a framework for prognostic assessment and precision therapy.
Publicações recentes
Metachronous bilateral renal cancer with immune checkpoint blockade-mediated eradication of bone metastasis: case report.
🥉 Relato de casoCase Report: A rare case of Pneumocystis jirovecii infection with left hydropneumothorax following immunotherapy for stage IVB clear cell renal cell carcinoma.
A probiotic bacterium modulates antitumour γδ T-cell responses in lung cancer.
Mechanistic study of MUC3A in promoting progression of clear cell renal cell carcinoma via the JAK‑STAT pathway.
📚 EuropePMC35.568 artigos no totalmostrando 189
Intra-arterial infusion of bevacizumab for the treatment of peritoneal metastatic high-grade renal cell carcinoma: a case report.
Frontiers in immunologyWhole-body magnetic resonance imaging for cancer screening in asymptomatic adults: a multicenter study.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)ODF3B Promotes the Progression of Clear Cell Renal Cell Carcinoma via the JAK/STAT Signaling Pathway.
Medical science monitor : international medical journal of experimental and clinical researchPreoperative assessment of split renal function in patients with renal cell carcinoma by APTw driven multiparameter MRI.
BMC medical imagingMAGI3 deficiency unleashes β-catenin conformational change to drive metastatic progression and mTOR inhibitor resistance in ccRCC.
Cell death & diseaseGenome-wide CRISPR screen identifies a cytokine-enhancer circuit driving HIF-2α activation in renal cancer.
The Journal of clinical investigationUnclear territory: navigating metastatic nonclear cell renal cell carcinoma.
Current opinion in oncologyShort and Long Non-Coding RNAs in Renal Cell Carcinoma.
Non-coding RNAPulmonary Metastases From Undiagnosed Prostate Cancer Mimicking Late Recurrence of Renal Cell Carcinoma: Diagnosis Confirmed by Thoracoscopic Biopsy.
CureusEpigenetic activation of VEGFA by SMARCD1 mediates tumor progression and bevacizumab resistance in clear cell renal cell carcinoma.
BMC cancerSETD2 methyltransferase activity promotes correct transcription initiation and termination.
EMBO reportsDR5/WDR12 balances p65 stability promoting sunitinib resistance in renal cell carcinoma.
Cell death and differentiationPatient-derived organoids in renal cell carcinoma: A review of methodologies and applications.
Urologic oncologySociety for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.
Journal for immunotherapy of cancerThe role of spinal stereotactic radiosurgery in the treatment of renal cell carcinoma spinal metastases.
Journal of neurosurgery. SpineRare renal tumor: a case report of collecting duct carcinoma and literature review.
Frontiers in oncologyA Life-Threatening Metastasis of Renal Cell Carcinoma: An Endotracheal Metastasis.
CureusIdentification of risk factors for the development and prognosis of bone metastases in renal cell carcinoma: development and validation of a predictive model.
American journal of cancer researchMetastatic renal cell carcinoma to the thyroid gland with tracheal invasion: A case report.
Radiology case reportsMakorin Ring Finger Protein 1 Inhibits Cell Proliferation in Renal Angiomyolipoma via the ERK/MAPK Signaling Pathway.
Kidney diseases (Basel, Switzerland)Intraventricular metastasis: A systematic review of patient demographics, clinical characteristics, and outcomes.
Neuro-ChirurgieSLAMF1 at the crossroads of immunity and disease: Biology, pathology, and therapeutic opportunities.
CytokineAn interpretable machine learning model based on habitat radiomics combined with deep learning for predicting the WHO/ISUP grade of patients with clear cell renal cell carcinoma.
BMC medical imagingMonogenic and Polygenic Risk for Kidney Cancer in Two Large Biobanks.
European urology oncologyEndothelial SMAD1-MCAM axis facilitates sunitinib resistance and progression of clear cell renal cell carcinoma via LAMB1-ITGB1 signaling.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapyMulti-omics profiling identifies ectopic olfactory receptors as putative drivers of tumor progression and prognostic indicators in clear cell renal cell carcinoma.
Clinical and experimental medicineTRIM21-Mediated ubiquitination of FBL suppresses PI3K/AKT signaling and tumor progression in clear cell renal cell carcinoma.
Cellular and molecular life sciences : CMLSPARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trial.
TrialsHemoperitoneum detected by peritoneal dialysis as presenting symptom of cytomegalovirus-associated colitis: a case report.
BMC nephrologyBridging urology and palliative care: a narrative review of current practice and evolving priorities.
Current opinion in urologyRenal cell carcinoma presenting with orbital metastasis as the initial symptom: A case report.
MedicineRecurrent Mental Cutaneous Metastases Secondary to Bilateral Renal Cell Carcinoma.
CureusRAB24 maps comprehensive clinical landscapes and mediates tumor malignant progression under the epigenetic regulation of miR-30b-3p and MMP11 in clear cell renal cell carcinoma.
Genes & diseasesZBED6-IGF2-PIK3C3 autophagy axis drives ccRCC progression: A multi-omics integration study.
iScienceA prospective head-to-head comparison of 18F-NYM005 PET/CT and 18F-FDG PET/CT in diagnosing renal cell carcinoma.
European journal of nuclear medicine and molecular imagingFUT8 reprograms glycolytic metabolism to promote PKM2 lactylation and drive clear cell renal cell carcinoma progression.
Cell death discoveryZDHHC9 palmitoylates LAMTOR1 to promote renal cell carcinoma malignant progression.
Cell death & diseaseA Systematic Review and Meta-Analysis of the Significance of Diabetes on Kidney Cancer Outcomes and the Role of Metformin.
Clinical genitourinary cancer[The effect of preoperative inflammatory indicators on the prognosis of patients with T1a renal cell carcinoma undergoing surgery and the construction of a predictive model].
Zhonghua yi xue za zhiComparison of clinical characteristics between patients with single mutation and co-mutation in hereditary renal cancer: a retrospective analysis of 115 patients with von Hippel-Lindau syndrome.
Journal of medical geneticsClinical characteristics and follow-up of 77 patients with pathogenic fumarate hydratase variants.
BJU internationalRenal Clear Cell Carcinoma Discovered Following Pyothorax: A Case Report.
CureusLate-Onset Normotensive Thrombotic Microangiopathy and Pyoderma Gangrenosum Following Nine Years of Sunitinib Therapy: A Case Report.
Kidney medicineUltra-late pancreatic metastases from renal cell carcinoma after nephrectomy: two case reports and a literature review.
Journal of surgical case reportsRenal sinus leiomyoma mimicking papillary renal cell carcinoma: A case report.
Radiology case reportsDevelopment of Celiac Disease After Immunotherapy: A Case Series.
Gastro hep advancesTAOK3 promotes ccRCC progression by phosphorylating ASAP2.
Biochimica et biophysica acta. Molecular basis of diseasePan-cancer multi-omics profiling of gasdermins identifies GSDMD as an immune-related prognostic biomarker in kidney renal clear cell carcinoma.
Discover oncologyCombinatorial immunotherapy drives exhaustion in tumor antigen-specific CD8+ T cells within the mouse renal tumor microenvironment.
Journal of immunology (Baltimore, Md. : 1950)Surgery and toceranib for renal cell carcinoma with caval thrombus in a dog.
The Canadian veterinary journal = La revue veterinaire canadienneCorrelation of mRENAL score with clinical outcomes after CT-guided renal cell carcinoma cryoablation: A retrospective observational study.
Qatar medical journalIncreased expression of CD36 and CD163 in clear cell renal cell carcinoma suggests an association between lipid transport and an "M2-like" macrophage phenotype.
Frontiers in immunologySurvivorship after Kidney Cancer in Children, Adolescents and Young Adults- What is Causing Death and When?
UrologyOxalate induces proliferation and mitochondrial metabolism in select clear cell renal cell carcinoma cell lines.
BMC cancerPercutaneous Cryoablation of Clinical T1b Renal Tumors: A Tertiary Cancer Center Experience.
Cardiovascular and interventional radiologyInitial and Repeat Metastasis-Directed Therapy in Systemic Therapy-Naïve Oligometastatic Renal Cell Carcinoma: Oncologic Outcomes and Risk-Based Stratification.
Annals of surgical oncologyUSP20 governs tyrosine kinase inhibitors resistance through ferroptosis evasion by targeting GPX4 in cancers.
Redox biology[Cryoablation for Renal Cell Carcinoma: Update on an Established Ablative Technique].
Aktuelle UrologieRadiotherapy Utilization Patterns Among Patients With Metastatic Renal Cell Carcinoma of the Spine: A National Claims Database Study.
American journal of clinical oncologyThe Cyclin C-CDK8/19 Mediator kinase module controls PRCC-TFE3 driven senescence in renal epithelium and tumorigenesis in TFE3-RCC.
Neoplasia (New York, N.Y.)A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J-ENCORE Study.
International journal of urology : official journal of the Japanese Urological AssociationDoes Tumor Grade Have any Prognostic Significance in Chromophobe Renal Cell Carcinoma: A Clinicopathological Study.
Journal of cancer & allied specialtiesA Survey of Oncologists' Perceptions and Opinions Regarding Brain Imaging in Metastatic Renal Cell Carcinoma Within the UK.
CureusProtocol for constructing an orthotopic mouse model of metastatic renal cell carcinoma.
STAR protocolsAdrenocortical Carcinoma as a Manifestation of Birt-Hogg Dubé Syndrome.
Endocrine-related cancerRecurrent spontaneous pneumothorax and surgical management in Birt-Hogg-Dubé syndrome: a case report.
International journal of surgery case reportsA case report of the world's biggest renal cell carcinoma successfully removed.
International journal of surgery case reportsNew-onset renal impairment following radical nephrectomy for renal cell carcinoma: a retrospective cohort study of clinical, intraoperative, and postoperative risk factors.
Therapeutic advances in urologyIL20RB promotes proliferation and migration in clear cell renal cell carcinoma and is associated with immune infiltration.
PeerJEpithelial-mesenchymal transition and sunitinib resistance in renal cell carcinoma: mechanisms and therapeutic strategies.
Frontiers in pharmacologyLarge sarcomatoid chromophobe renal cell carcinoma with tumor thrombus extending into the inferior vena cava: a case report on the challenges and lessons from a fatal outcome.
Annals of translational medicineFloSeal® for Parenchymal Hemostasis in Robot-Assisted Partial Nephrectomy: Technical Description and a Report of Two Cases.
CureusSurgical Resection of Abdominal Solid Organ Tumors With Inferior Vena Cava Extension: A Single-Center Experience With Long-Term Follow-Up.
CureusNutrient intake and renal cancer: molecular pathways and mechanistic insights into the protective role of dietary components.
Frontiers in nutritionSafety, Efficacy, and Intermediate‑Term Outcomes of CT‑Guided Cryoablation of T1 Renal Cell Carcinoma: A Retrospective Single‑Center Study.
Journal of the Belgian Society of RadiologyTaraxasterol Suppresses Renal Cell Carcinoma Progression by Modulating Cell Cycle Progression and Apoptosis.
Anti-cancer agents in medicinal chemistryPredicting aggressiveness of clear cell renal cell carcinoma via mri using artificial intelligence: implications for surgical planning in a retrospective multicenter study.
Scientific reportsSterotactic ablative radiotherapy vs. thermal ablation of localized renal cell carcinoma: Is there a preferred second-line management option?
Urologic oncologyProton beam therapy versus photon therapy for multiple malignancies: An umbrella systematic review and meta-analysis.
Critical reviews in oncology/hematologySerum Chemokines CCL3 and CCL7 as Complementary Diagnostic Biomarkers Across Tumor Grades in Clear Cell Renal Cell Carcinoma.
International journal of molecular sciencesUpdates on Clinical Trials and Molecular Characteristics of Locally Advanced and Oligometastatic Renal Cell Carcinoma.
International journal of molecular sciencesOpportunities and Challenges of Visual Large Language Models in Imaging Diagnostics: Lessons from Brain Metastasis Detection in Clinical MRI.
Diagnostics (Basel, Switzerland)VEGF-TKI Outcomes in Metastatic Renal Cell Carcinoma According to Prior Immune Checkpoint Inhibitor or VEGF-TKI: A Scoping Review and Exploratory Analysis.
CancersAngiogenesis-Informed Preoperative CT Radiogenomics Predicts Overall Survival in Clear Cell Renal Cell Carcinoma: Development and External Validation.
CancersImpact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk-Stratified Analysis.
Journal of clinical medicineDPP9 inhibition boosts antitumor immunity by disrupting BRISC-mediated PD-L1 expression in clear cell renal cell carcinoma.
Cell death and differentiationLiquid-Based Cytologic Features of a Thyroid TFE3-Rearranged PEComa-Like Neoplasm: A Case Report.
Diagnostic cytopathologyThe Staging of High-risk And non-metastatic Renal cell carcinoma Preoperatively (SHARP) Model predicts pathologic T3 stage for neoadjuvant clinical trial enrollment.
UrologyMultidisciplinary therapy managements in endometrial and renal cancer patients treated with pembrolizumab and lenvatinib: a virtuous circle between oncologists and organ specialists.
Critical reviews in oncology/hematologyTargeting pH regulation in cancer: combined mild alkaline treatment and NHE1 inhibition as a potential therapy for clear cell renal cell carcinoma.
Molecular and cellular biochemistryA new cuproptosis-associated lncRNA signature predicts the prognosis of clear cell renal cell carcinoma patients.
Discover oncologyStereotactic ablative radiotherapy: an effective alternative for pancreatic metastases originating from renal cell carcinoma-experience from two European institutions.
Clinical & experimental metastasisApplication of carbonic anhydrase IX-targeted radiopharmaceuticals in the diagnosis and treatment of clear cell renal cell carcinoma (Review).
Oncology lettersMachine learning-derived AS and AIS scores leverage BCAA metabolism and IL4I1 activity for prognosis and tailored therapy in ccRCC.
Frontiers in cell and developmental biologyFunctional and Survival Outcomes of Partial Versus Radical Nephrectomy in Renal Cell Carcinoma Patients With Pre-Existing Chronic Kidney Disease: A Real-World Study.
World journal of oncologyTertiary lymphoid structures in genitourinary cancers: a comprehensive review.
Frontiers in oncologyThe prognostic impact of systemic inflammation and nutritional indicators on targeted therapy for renal cell carcinoma: a systematic review and meta-analysis.
Frontiers in nutritionElevated DOCK4 expression correlates with favorable prognosis and immune infiltration in clear cell renal cell carcinoma.
Annals of medicineImpact of Perioperative Proton Pump Inhibitors on Renal Cancer Progression. A Retrospective Study.
Cancer medicinePattern and Clinical Significance of CA19-9 Expression in Human Cancer: A Tissue Microarray Study on 14,966 Tumors.
Cancer medicineFeasibility of Spectral Computed Tomography Color Overlay to Augment Tumor Visibility for Renal Cryoablation.
Cardiovascular and interventional radiologyImpact of high relative dose intensity on effectiveness and treatment continuity of IO-TKI therapy in Japanese advanced renal cell carcinoma.
Scientific reportsVHL synthetic lethality screens uncover CBF-β as a negative regulator of STING.
Nature communicationsValue of High Frame Rate Contrast-enhanced Ultrasound in Evaluating Vascular Morphology of Renal Cell Carcinoma.
Current medical imaging[rare subtype of kidney cancer - Pigmented microcystic chromophobe carcinoma].
Magyar onkologiaComprehensive immunohistochemical and molecular characterization of paratesticular clear cell papillary cystadenomas: A multi-institutional study of 14 cases.
Annals of diagnostic pathologyA lactylation-related gene signature predicts prognosis and immunotherapy response in clear cell renal cell carcinoma based on machine learning and multi-omics analysis.
Discover oncologyComparative outcomes and costs of robotic assisted, laparoscopic, and open partial nephrectomy: a contemporary analysis of national inpatient sample data.
World journal of urologyAnastomosing hemangioma of the renal pelvis: The first case report from Vietnam.
Urology case reportsSymptomatic renal tumor in mid-pregnancy managed with nephrectomy and term vaginal delivery: a case report and literature review.
International journal of surgery case reportsRenal schwannoma appears on imaging as renal cell carcinoma: a case report.
Journal of medical case reportsUltrasound-assisted diagnosis and ultrasound-guided radiofrequency ablation of renal cell carcinoma in a patient with autosomal dominant polycystic kidney disease: a case report with two-year follow-up.
BMC nephrologyBaseline and three-month De Ritis ratio and gamma-glutamyltransferase as prognostic biomarkers in metastatic renal cell carcinoma treated with targeted therapy.
Scientific reportsGamma-aminobutyric acid transaminase mediates tumor suppression in renal cell carcinoma through the cGAS-STING-interferon-β axis.
Scientific reportsLong non-coding RNA PSMB8-AS1 as a potential biomarker for postoperative recurrence in patients with Fuhrman grades 1-3 clear cell renal cell carcinoma.
PloS oneMulti-omics integration constructs a senescence-based prognostic model and identifies EIF4EBP1 as a therapeutic target in clear cell renal cell carcinoma.
Discover oncologyBarriers to Health Care Access and Use among Racial and Ethnic Minorities with Renal Cell Carcinoma.
Urology practiceIn vivo self-assembled siRNAs targeting VEGFR2 and mTOR for renal cell carcinoma treatment.
Asian journal of pharmaceutical sciencesWhy Does DNA Methylation Accumulate at CpG Loci?: Sequential Analysis of Cdkn2a/p16Ink4a Gene Methylation in a Rat Renal Tumor Model.
Acta histochemica et cytochemicaCurrent research on the HIF-2α-EPO-Hb axis in hypoxic environments: from molecular mechanisms to clinical.
Frontiers in medicineOne size does not fit all: rethinking IO-TKI use in favorable-risk metastatic ccRCC.
Frontiers in oncologyCombined assessment of ERO1A expression and CD163+ tumor-associated macrophage infiltration is superior to traditional assessment methods in predicting clear cell renal cell carcinoma prognosis.
Frontiers in oncologyAnticoagulant outcomes in managing tumor thrombus: a systematic review.
Frontiers in oncologyIdentification of prognostic factors for postoperative recurrence-free survival in T2-stage renal cell carcinoma: a retrospective cohort study.
Translational andrology and urologyFirst report of transumbilical robotic-assisted single-port laparoscopic partial nephrectomy using a domestic Shurui® robotic system: a report of two cases.
Translational andrology and urologyUSP10 regulates HIF2α stability by deubiquitinating HIF2α regardless of VHL status in kidney cancer.
Translational andrology and urologyDevelopment and validation of a risk classification integrating the location index to predict renal function after robotic partial nephrectomy.
Scientific reportsBaseline serum folic acid as a prognostic biomarker in metastatic renal cell carcinoma treated with targeted therapy.
Discover oncologyHIF-2α Inhibitor Combinations Knock Back Kidney Cancer in Two Trials.
Cancer discoveryTranscriptomic profiling of clear cell renal cell carcinoma reveals age-dependent molecular signatures and clinical stratification patterns.
PloS oneNoninvasive Differentiation of Indolent from Aggressive Renal Neoplasms with MR Fingerprinting Combined with Diffusion/Perfusion MRI.
RadiologyLinezolid-induced Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature.
Clinical neuropharmacologyMicroRNA prognostic markers for immune checkpoint inhibitor success in urologic cancers.
ImmunotherapyA Case of Reactive Lymphoid Hyperplasia That Is Difficult to Differentiate From Renal Cancer With Lymph Node Metastasis.
IJU case reportsMultiphase CT-based deep learning radiomics nomogram models for preoperative WHO/ISUP grading of clear cell renal cell carcinoma: a two-center validation study.
BMC medical imagingPhosphoethanolamine cytidylyltransferase 2 exerts an anti-tumor role in clear cell renal cell carcinoma by modulating the hippo/YAP1 signaling pathway in a PPP2R1A-dependent manner.
Toxicology and applied pharmacologyRobot-assisted versus open surgery for multiple ipsilateral renal tumors: a multicenter matched cohort study (UroCCR-60).
Journal of robotic surgeryImpact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome-immune cell signatures.
Cancer immunology, immunotherapy : CIIArtificial intelligence in urological malignancy diagnosis and prognosis: current status and future prospects.
The Canadian journal of urologyMIRit: an integrative R framework for the identification of impaired miRNA-mRNA regulatory networks in complex diseases.
Bioinformatics advancesGFPT2 drives sunitinib resistance of renal cell carcinoma via enzyme-dependent and -independent manners.
International journal of biological sciencesRenal cell carcinoma incidence and mortality in California: a population-based study of sociodemographic patterns and temporal trends from 1988 through 2019.
Lancet regional health. AmericasEctopic adrenal nodular hyperplasia mimicking right upper polar renal cell carcinoma: a case report and literature review.
Frontiers in oncologyPatients' knowledge, attitudes, preferences regarding kidney cancer screening, and factors influencing participation intentions: a qualitative study.
Frontiers in oncologyIFI44 Promotes Clear Cell Renal Cell Carcinoma Progression via PRDX1 and Predicts Poor Prognosis.
Research (Washington, D.C.)Specific in vivo detection of V2R-positive metastatic ccRCC using a toxin-based PET radioligand.
TheranosticsConnective tissue growth factor contributes to resistance to anti-angiogenic therapies in renal cancer.
TheranosticsA Case of Bilateral Renal Cancer in a Dialysis Patient With Enlarged ACDK Treated With Staged Laparoscopic Nephrectomy.
IJU case reportsDeterminants of pancreatic tropism in metastatic renal cell carcinoma.
JCI insightClear Cell Papillary Renal Cell Tumor Revisited: Comparison of Histologic and Immunohistochemical Profiles in Relation to VHL Allelic Status.
The American journal of surgical pathologyImmuno-molecular features and therapeutic implications of brain metastases in clear cell renal cell carcinoma patients.
Genes and immunityThe oncovascular surgeon in modern surgical oncology: A literature review.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologySurvival outcomes after surgical treatment for non-clear cell renal cell carcinoma with tumor thrombus extension: a population-based cohort study.
World journal of urologySarcomatoid Renal Cell Carcinoma: Biological Features and Therapeutic Implications-A Narrative Review.
Current urology reportsDNA methyltransferase inhibition is a therapeutic vulnerability in VHL-deficient renal cell carcinoma cells.
Experimental & molecular medicineNode Positive Resected Renal Cell Carcinoma Portends a Poor Prognosis: Results From the Canadian Kidney Cancer Collaboration.
Clinical genitourinary cancerInhibitory effects and molecular mechanisms of Aristolochic acids on human and rat placental 3β-hydroxysteroid dehydrogenases.
Journal of ethnopharmacologyReal-World Outcomes in Advanced Clear Cell Renal Cell Carcinoma: A Retrospective Analysis Comparing New Zealand and Australian Cohorts.
JCO global oncologyMulti-omics analysis suggests ZDHHC18 as a potential risk factor for clear cell renal cell carcinoma linked to myeloid DC morphology.
Discover oncologyALK-Rearranged Renal Cell Carcinoma: Morphologic Spectrum and Genomic Landscape From a Multi-Institutional Cohort of 16 Cases.
The American journal of surgical pathologyEmerging role of functional imaging in renal cell carcinoma: from morphology to molecular phenotyping with PET/computed tomography.
Current opinion in oncologyReliable Detection of SGLT2 Protein by Knockout-Based Antibody Characterization.
Hypertension (Dallas, Tex. : 1979)Case Report: A patient with metastatic fumarate hydratase-deficient renal cell carcinoma associated with leiomyomatosis: real-world clinical insights on systemic therapy and liver-directed SBRT.
Frontiers in oncologyStudy on the prediction of postoperative metastasis in renal cancer using perirenal fat CT radiomics combined with clinical features.
Frontiers in oncologyImpact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 study.
Frontiers in oncologyClear cell renal cell carcinoma combined with intravascular large B-cell lymphoma: a case report and review of the literature.
Frontiers in oncologyCLINICAL CASE OF COMPLEX RADICAL TREATMENT OF METASTATIC PROGRESSION TO RARE SITE OF PRIMARY ORGAN CONFINED CHROMOPHOBE RENAL CELL CARCINOMA TREATED WITH LAPAROSCOPIC PARTIAL NEPHRECTOMY.
Experimental oncologyGut microbiota modulation of epigenetic target EHMT2: Lacticaseibacillus rhamnosus Fb7-311 regulated renal cell carcinoma apoptosis and metastasis.
Experimental & molecular medicinePellino1-mTOR/S6K1 signaling axis is a key pathogenesis for the development of polycystic kidney disease.
Cell death & diseaseNivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.
Annals of oncology : official journal of the European Society for Medical OncologyOutcomes after Pancreatic Resections for Secondary Tumours in the Pancreas: A Single Centre Experience.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractClinical, pathologic, and molecular profiles of sarcomatoid and rhabdoid differentiated clear cell renal cell carcinoma: A series of 21 tumors.
Human pathologyICG fluorescence imaging in sentinel lymph node identification: toward a standardized protocol in paediatric renal tumour surgery.
Pediatric surgery internationalCitronellol potentiates sunitinib efficacy in renal cell carcinoma by targeting JAK2/STAT3 signaling pathway.
Naunyn-Schmiedeberg's archives of pharmacologyNitroimidazole-Containing [68Ga]Ga-IPM-N001 as a New CAIX-Targeting Radionuclide Tracer.
Journal of medicinal chemistryUnraveling the role of LINC02657 in clear cell renal cell carcinoma: insights into tumor aggression, immune modulation, and treatment response.
Frontiers in immunologyHIF2 drives PTHrP-mediated cancer cachexia.
Trends in molecular medicineDUSP15 exhibits structural and dynamical signatures inconsistent with catalytic phosphatase activity.
Biochimica et biophysica acta. Proteins and proteomicsPrediction of Distant Metastasis in Renal Cell Carcinoma Using Machine Learning Algorithms: A Multicenter Cohort Study.
Cancer control : journal of the Moffitt Cancer CenterHereditary Leiomyomatosis and Renal Cell Carcinoma.
JAMA dermatologyActivation of the PI3K/AKT pathway by EDIL3 induces EMT and promotes tumor progression in clear cell renal cell carcinoma.
Molecular genetics and genomics : MGGImmunohistochemical expression of GPNMB in TFEB-rearranged and TFEB-amplified renal cell carcinomas.
Virchows Archiv : an international journal of pathologyEarly-Onset Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Following First-Cycle Pembrolizumab: Diagnostic Challenges and Management Strategies.
CureusRapidly Progressive Overlap of Immune Checkpoint Inhibitor-Induced Myositis and Myasthenia Gravis: Diagnostic and Therapeutic Challenges.
CureusIdentifying new targets for the treatment of renal medullary carcinoma: from biological hallmarks to precision therapies.
Future oncology (London, England)Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma.
Journal for immunotherapy of cancerNeoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual MeetingModified clear cell likelihood score and a new CAT score in the assessment of indeterminate small renal masses.
Journal of cancer research and clinical oncologyStaging and imaging-based prognostication in renal cell carcinoma: current guidelines and practical considerations.
Abdominal radiology (New York)Associações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Carcinoma de células renais.
É de uma associação que acompanha esta doença? Fale com a gente →
Doença com base genética
Um médico geneticista pode ajudar no diagnóstico de Carcinoma de células renais e no aconselhamento genético da família.
Doenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Perguntas frequentes
O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu
É um tumor maligno que se origina nas células epiteliais glandulares do rim, conhecido popularmente como câncer de rim. A sua prevalência é estimada em 1 a 5 pessoas a cada 10.000 e seu início habitual ocorre na idade adulta.
Referências
Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete
10 publicações do grafo RarasNet (PubMed) · 7 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Citar este verbete
Raras. (s.d.). Carcinoma de células renais. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/carcinoma-de-celulas-renais
Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
Carcinoma de células renais
📋 Origem dos dados
Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.
- Doença rara (ontologia)
- fonte: Orphanet
- Identificador unificado
- fonte: MONDO
- Codificação WHO/SUS
- fonte: WHO ICD-10 / DATASUS
- CID-11 (futuro)
- fonte: WHO ICD-11
- NIH/GARD
- fonte: GARD (NIH)
- Indexação biomédica
- fonte: MeSH (NLM)
- Dado público estruturado
- fonte: Wikidata
- Medicamentos aprovados FDA
- fonte: FDA OpenFDA
- Reposicionamento
- fonte: Drug Repurposing Hub
- Ensaios clínicos
- fonte: ClinicalTrials.gov
